Solo.io develops open source and enterprise software that helps enterprises adopt and operate innovative cloud native technologies like microservices, serverless and service mesh. Founded in 2017 in Cambridge, MA, Solo.io is backed by Redpoint Ventures and True Ventures.
Analytics
50 - 250 employees
Boston, Massachussets, United States
Ramp is building the world's first finance automation platform designed to save businesses time and money. Ramp offers 5-in-1 software that consolidates corporate cards, expense management, bill payments, accounting, and reporting into one simple and free solution. More than 5,000 businesses are using Ramp, from some of the fastest growing startups and unicorns like Ro, Faire, Marqeta, ClickUp, and Applied Intuition, to established businesses across the US including Bristol Hospice, Walther Farms, Douglas Elliman, and Planned Parenthood.
Founded in 2019, Ramp is NYC's fastest growing startup, having achieved a unicorn valuation of $3.9 billion in just over 2 years. Ramp has raised $620 million in funding from investors including Founders Fund, Stripe, Goldman Sachs, Coatue Management, D1 Capital Partners, Redpoint Venture, Thrive Capital, Altimeter, Iconiq, Spark Capital, and the Box Group, as well as over 100 angel investors who were founders or executives of leading companies. Ramp is part of the Forbes Fintech 50, LinkedIn Top Startups of 2021, and Fast Company's Best Workplaces for Innovators program.
Fintech
1000+ employees
Boston, Massachussets, United States
Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. We are advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Learn more at kymeratx.com.
Biotech
50 - 250 employees
Boston, Massachussets, United States